Credit Suisse Ag Coherus Bio Sciences, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 58,431 shares of CHRS stock, worth $62,521. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,431

Previous 320,501 81.77%

Holding current value

$62,521

Previous $1.07 Million 86.97%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.02 - $3.14 $529,381 - $822,899	-262,070 Reduced 81.77%	58,431 $139,000
Q4 2023 Feb 08, 2024	SELL	$1.59 - $3.85 $69,967 - $169,419	-44,005 Reduced 12.07%	320,501 $1.07 Million
Q3 2023 Nov 13, 2023	SELL	$3.74 - $5.45 $66,762 - $97,287	-17,851 Reduced 4.67%	364,506 $1.36 Million
Q2 2023 Aug 11, 2023	SELL	$3.79 - $8.3 $105,782 - $231,661	-27,911 Reduced 6.8%	382,357 $1.63 Million
Q1 2023 May 10, 2023	SELL	$5.89 - $10.52 $166,427 - $297,253	-28,256 Reduced 6.44%	410,268 $2.81 Million
Q4 2022 Feb 13, 2023	SELL	$5.69 - $10.07 $199,645 - $353,326	-35,087 Reduced 7.41%	438,524 $3.47 Million
Q3 2022 Nov 10, 2022	BUY	$7.17 - $13.87 $1.58 Million - $3.06 Million	220,374 Added 87.02%	473,611 $4.55 Million
Q2 2022 Aug 12, 2022	BUY	$5.86 - $13.23 $237,699 - $536,648	40,563 Added 19.07%	253,237 $1.83 Million
Q1 2022 May 16, 2022	BUY	$10.92 - $16.41 $95,440 - $143,423	8,740 Added 4.29%	212,674 $2.74 Million
Q4 2021 Feb 14, 2022	SELL	$15.81 - $18.99 $2.51 Million - $3.01 Million	-158,580 Reduced 43.74%	203,934 $3.25 Million
Q3 2021 Nov 12, 2021	BUY	$12.68 - $17.79 $2.14 Million - $3 Million	168,621 Added 86.97%	362,514 $5.83 Million
Q2 2021 Aug 16, 2021	SELL	$12.95 - $15.41 $607,471 - $722,867	-46,909 Reduced 19.48%	193,893 $2.68 Million
Q1 2021 May 14, 2021	SELL	$14.42 - $21.39 $334,082 - $495,563	-23,168 Reduced 8.78%	240,802 $3.52 Million
Q4 2020 Feb 12, 2021	BUY	$16.56 - $18.94 $184,312 - $210,802	11,130 Added 4.4%	263,970 $4.59 Million
Q3 2020 Nov 13, 2020	SELL	$17.41 - $19.89 $971,965 - $1.11 Million	-55,828 Reduced 18.09%	252,840 $4.64 Million
Q2 2020 Aug 12, 2020	BUY	$14.43 - $19.16 $1.93 Million - $2.57 Million	133,939 Added 76.66%	308,668 $5.51 Million
Q1 2020 May 13, 2020	SELL	$11.67 - $22.53 $1.27 Million - $2.44 Million	-108,438 Reduced 38.29%	174,729 $2.83 Million
Q4 2019 Feb 12, 2020	SELL	$16.33 - $21.37 $1.66 Million - $2.17 Million	-101,690 Reduced 26.42%	283,167 $5.1 Million
Q3 2019 Nov 12, 2019	BUY	$16.3 - $23.37 $4.02 Million - $5.77 Million	246,898 Added 178.96%	384,857 $7.8 Million
Q2 2019 Aug 14, 2019	SELL	$13.1 - $22.1 $586,814 - $989,969	-44,795 Reduced 24.51%	137,959 $3.05 Million
Q1 2019 May 14, 2019	SELL	$8.38 - $15.5 $45,050 - $83,328	-5,376 Reduced 2.86%	182,754 $2.49 Million
Q4 2018 Feb 13, 2019	SELL	$8.65 - $16.28 $13,511 - $25,429	-1,562 Reduced 0.82%	188,130 $1.7 Million
Q3 2018 Nov 13, 2018	SELL	$14.45 - $20.25 $427,127 - $598,569	-29,559 Reduced 13.48%	189,692 $3.13 Million
Q2 2018 Aug 14, 2018	BUY	$10.25 - $17.45 $734,832 - $1.25 Million	71,691 Added 48.58%	219,251 $3.07 Million
Q1 2018 May 15, 2018	BUY	$9.1 - $13.7 $326,289 - $491,227	35,856 Added 32.1%	147,560 $1.63 Million
Q4 2017 Feb 14, 2018	SELL	$8.35 - $14.4 $256,996 - $443,203	-30,778 Reduced 21.6%	111,704 $982,000
Q3 2017 Nov 14, 2017	SELL	$11.1 - $14.5 $80,697 - $105,415	-7,270 Reduced 4.85%	142,482 $1.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	149,752	149,752 $2.15 Million

Others Institutions Holding CHRS

# of Institutions

130

Shares Held

67.8M

Call Options Held

1.68M

Put Options Held

91.8K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $83.2M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account